Bioxcel Therapeutics Secures Patents for Agitation Treatments

Bioxcel Therapeutics Inc (BTAI) has released an update.

BioXcel Therapeutics, Inc. has achieved significant milestones by securing the allowance of multiple U.S. patents for their proprietary treatments for agitation in Alzheimer’s, schizophrenia, and bipolar disorder patients using dexmedetomidine in various oromucosal forms. The granted patents extend protection until dates ranging from 2037 to 2043, with the latest patent expected to join the eight others listed in the FDA’s Orange Book, bolstering the company’s intellectual property portfolio and potentially enhancing shareholder value through extended market exclusivity.

For further insights into BTAI stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.